Market research
PSTV Plus Therapeutics Inc
NASDAQ USD Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
- Market cap
- 27M
- P/E ratio
- 0.18
- Analyst target
- 36
- Dividend yield
- Not available
- Beta
- 1.42
Profile
Company facts
- Exchange
- NASDAQ
- Currency
- USD
- Sector
- Healthcare
- Industry
- Biotechnology
- ISIN
- US72941H8060
- Market cap
- 27M
- P/E ratio
- 0.18
- Analyst target
- 36
- Dividend yield
- Not available
- Beta
- 1.42
About
About Plus Therapeutics Inc
Plus Therapeutics, Inc., a clinical-stage pharmaceutical company, focuses on the development, manufacture, and commercialization of treatments for patients with cancer. The company's lead radiotherapeutic candidate is rhenium obisbemeda, a patented radiotherapy for patients with central nervous system and other cancers, including recurrent glioblastoma, leptomeningeal metastases, and pediatric brain cancers. It also develops Rhenium-188 NanoLiposome Biodegradable Alginate Microsphere to treat various solid organ cancers, such as primary and secondary liver cancers by intra-arterial injection. In addition, it develops and commercializes laboratory-developed tests comprising the CNSide Test to identify tumor cells that have metastasized to the central nervous system in patients with carcinomas and melanomas. The company was formerly known as Cytori Therapeutics, Inc. and changed its name to Plus Therapeutics, Inc. in July 2019. Plus Therapeutics, Inc. was founded in 1996 and is headquartered in Houston, Texas.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the PSTV discussion.
5 years, 4 months ago
Plus Therapeutics, Inc is currently in a long term downtrend where the price is trading 2.8% below its 200 day moving average.
From a valuation standpoint, the stock is 97.4% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 34.3.
Plus Therapeutics, Inc's total revenue sank by 100.0% to $0 since the same quarter in the previous year.
Its net income has dropped by 505.8% to $-4M since the same quarter in the previous year.
Finally, its free cash flow fell by 435.7% to $-3M since the same quarter in the previous year.
Based on the above factors, Plus Therapeutics, Inc gets an overall score of 1/5.